### TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE

#### **Peter Palese**

#### Icahn School of Medicine at Mount Sinai New York

**OPTIONS IX 8-26-16** 

ISIRV - Options IX for the Control of Influenza

Peter Palese, PhD Professor and Chair Department of Microbiology Icahn School of Medicine, New York


Mount Sinai has submitted patent applications for a universal influenza virus vaccine


Work has been supported by the NIH, The Bill & Melinda Gates Foundation, GSK

My presentation does not include discussion of off-label or investigational use.

## Surface glycoprotein diversity of different viruses

Influenza virus HA diversity







Similar variation for influenza, HIV and HCV<sub>0.05</sub>

**F. Krammer** 

#### EIGHTEEN SUBTYPES OF INFLUENZA A VIRUS HEMAGGLUTININS



#### Influenza viruses circulating in the human population



#### AVIAN INFLUENZA VIRUSES INFECTING HUMANS

H5N6	China	2016
H7N9	China	2015, 2014, 2013
H10N8	China	2013
H6N1	Taiwan	2013
H10N7	Australia, Egypt	2010,2004
H7N3	Mexico,UK,Canada,Italy 201	2,2006,04,03
H7N2	UK,USA	2007,2003
H9N2	Hong Kong	1999
H5N1	Asia, Europe, Africa, Hong Kong	2015-2003 , 1997
H7N7	Netherlands,UK,USA,Austr.,USA	2003,96,80,77,59

## INFLUENZA VIRUS VACCINES

## INACTIVATED LIFE ATTENUATED RECOMBINANT

### INFLUENZA VIRUS VACCINE STRAINS 2016-2017

#### A/California/7/2009 (H1N1)pdm09 A/Hong Kong/4801/2014 (H3N2)

B/Phuket/3073/2013 B/Brisbane/60/2008


- INFLUENZA VIRUS VACCINES ARE UNIQUE.
- THEY HAVE TO BE GIVEN **ANNUALLY, BECAUSE NOVEL** VACCINE FORMULATIONS HAVE TO BE PREPARED REFLECTING THE RAPID **ANTIGENIC CHANGE OF THE VIRUS**.

#### Antigenic diversity: analysis of the flexible influenza A virus and rigid measles virus glycoproteins


#### Nicholas Heaton, PhD Ben Fulton

Palese Lab Icahn School of Medicine at Mount Sinai


#### INSERTION MUTATIONS ARE TOLERATED IN THE HEAD OF THE HEMAGGLUTININ After



## The measles virus glycoproteins (and the polymerase) are resistant to insertions




### TOLERANCE OF THE INFLUENZA A VIRUS AND OF MEASLES VIRUS GENOMES



### HOW CAN WE DO BETTER?

#### UNIVERSAL INFLUENZA VIRUS VACCINES

#### Vision for a human universal influenza virus vaccine



pre-existing immunity against e.g. H1

boost with cH5/1 construct


boost with cH6/1 construct

FLORIAN KRAMMER ADOLFO GARCÍA-SASTRE PETER PALESE


### APPROACHES

- ADJUVANTS
- MVA-VECTORED
- M2e-BASED
- EPITOPES/PEPTIDES
- NEURAMINIDASE
- COBRA (computationally optimized broadly reactive antigens)
- STALK ONLY, HEADLESS HEMAGGLUTININ
- CHIMERIC HEMAGGLUTININ


# Induction of protective levels of stalk-reactive antibodies using chimeric HA constructs in mice



# Induction of protective levels of stalk-reactive antibodies using chimeric HA constructs in mice




#### Induction of protective levels of stalk-reactive antibodies using chimeric HA constructs in mice




matched vaccine (pos. contr.)

# Induction of protective levels of stalk-reactive antibodies using chimeric HA constructs in mice




#### Vaccination with cHA constructs protects from pH1N1 (A/Netherlands/602/09) challenge



Similar results for A/PR/8/34 H1N1 and A/FM/1/47 challenges

Krammer et al. JVI, 87, 6542,2013


#### cHA constructs protect mice from heterosubtypic challenge




- positive control (matched inactivated)
- CH9/1 DNA + H1 protein/cH6/1 protein + cH5/1 protein/H1
- protein cH9/1 DNA + BSA +BSA


cH5/1 (H5 challenge) or cH6/1 (H6 challenge) protein was replaced by full length H1 protein to exclude head-based protection


#### cHA constructs protect ferrets from pH1N1 challenge






Krammer et al., JVI Jan. 8, 2014









#### Protection is antibody mediated


#### ELISA reactivity to Cal09 Passive transfer of serum (pH1N1) protein protects from viral challenge



### **Targeting group 2 HA viruses**



## Protection against group 2 HA expressing viruses in the mouse model




cH4/3 DNA	cH5/3 protein	cH7/3 protein	Phil/82 (H3N2)
PRIME	BOOST	BOOST	X/31 (H3N2) 1968 Rhea (H7N1)

<u>Control groups:</u> cH4/3 DNA + BSA + BSA naïve (neg. contr.) matched vaccine (pos. contr.)

#### CHALLENGE

Margine et al., JVI, 87,10435, 2013

#### Group 2 cHA vaccine protects against challenge with novel H7N9\*virus




\*cH7/3 protein was replaced by full length H3 protein for the H7N1 challenge group


Krammer et al. JVI,88, 2340, 2014

### WHAT IS THE MECHANISM BY WHICH THESE BROADLY PROTECTIVE STALK-SPECIFIC ANTIBODIES MEDIATE THEIR ANTIVIRAL ACTIVITY?

#### medicine Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus *in vivo*




Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus *in vivo* 



Antibody-dependent Cell-mediated Cytotoxicity (ADCC) can be induced by stalkspecific, but not head-specific antibodies.

DiLillo et al. Nature Medicine 2014

## Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)




#### Can we elucidate the role epitope location plays in the induction of ADCC by broadly cross-reactive hemagglutinin antibodies?

#### Yes, by introducing FLAG epitopes into different locations in the viral hemagglutinin

Paul Leon, Wenqian He, Caitlin Mullarkey, Mark Bailey, Matt Miller, Florian Krammer, Gene Tan

#### A stalk-based FLAG epitope can induce FcyR-mediated effector function



#### Why do antibodies targeting the hemagglutinin head domain lack the ability to optimally induce ADCC activity?


#### **Disruption of sialic acid engagement**

• Blocking with Head-specific F(ab)<sub>2</sub>

• Blocking with 6' Sialyllactose

• Mutating Y108F in Receptor Binding Site

## Head-specific F(ab)<sub>2</sub> prevents ADCC induction of stalk-specific 6F12 mAb




#### **Disruption of sialic acid engagement**

• Blocking with Head-specific F(ab)<sub>2</sub>

• Blocking with 6'-sialyllactose

• Mutating Y108F in Receptor Binding Site

## 10 mM of 6'-sialyllactose decreases ADCC induction of stalk-specific antibodies




#### **Disruption of sialic acid engagement**

• Blocking with Head-specific F(ab)<sub>2</sub>

• Blocking with 6' Sialyllactose


• Mutating Y108F in Receptor Binding Site

#### Y108F mutation lowers RLU values when compared to WT Cal09



Y108F plasmid was generated and provided by Madhu

#### Two-contacts model for optimal induction of ADCC by influenza virusspecific mAbs



#### Property of the US Government cH5/1N1 GMOs contained inside

A/California/04/2009-(cH5/1N1)-PR8-IDCDC-RG37 Storage Conditions: 2-8°C Monovalent Pooled Harvest

3-1

Contract Nbr.: HHSO100201200011I Order Nbr.: HHSO10033005T Bottle 1 of 1

DOM: 29/08/2013


#### Property of the US Government

1405 000

cH5/1N1 GMOs contained inside Bottie 1 of 1 DOM: 29/08/2013 Bo Storage Conditions: 2-8°C Monovalent Pooled Harvest

#### bioCSL

MPH		29/08/14
Date of MPH Pre	29/08/14 IVV (Split Vinon	
Product:		00011494
Lot No:		AMethan
Strain:		VI-1593 MI
Seed Lot:		VI-1593 Proc.Stage: MI
Operators:	Pmu HU	
Bottle Tare:	5078	-9 29/08/15
Expiry:		



Start Frish biai Mar Mir Mir

ARHI

MPH Date of Product Lot No: Strain:

bioCSL

5279 C

Property of the US

Government cH8/1N1 GMOs contained inside

tract Nbr.: HHSO1002012000

ON TEST


#### cH8/1N1 GMOs contained inside

Contract Nbr.: HHSO1002012000111 Order Nbr.: HHSO10033005T Strain: A/mallard/Sweden/24/2002-California/04/2009-(cH8/1N1)-PR8-IDCDC-RG38A Seedlot: VI-1592 Bottle 1 of 1 DOM: 28/08/2013 Storage Conditions: 2-8°C Monovalent Pooled Harvest

#### SUMMARY

Towards a universal influenza virus vaccine by reducing the immunodominance of the hemagglutinin head and thereby increasing the immunogenicity of the hemagglutinin stalk and of the neuraminidase

# Vision for a human universal influenza virus vaccine



FLORIAN KRAMMER ADOLFO GARCÍA-SASTRE PETER PALESE

#### **SUMMARY (cont.)**

#### MECHANISM OF ADCC INDUCTION (TWO-CONTACTS MODEL)

- The location of a FLAG-Tag epitope plays a critical role in determining the level of Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) induction
- The ability of the hemagglutinin to bind to effector cells via its sialic acid receptor is required for optimal ADCC induction
- By blocking/mutating the sialic acid receptor binding site with F(ab)<sub>2</sub>, 6'-sialyllactose or a Y108F mutation, ADCC induction can be lowered substantially

#### ACKNOWLEDGEMENTS

FLORIAN KRAMMERJEFF RAVETCH RUADOLFO GARCÍA-SASTREP. WILSON UCSRIRAM SUBRAMANIAM NIH

TAIA WANGNATALIE PICAMATTHEW MILLERJOHN STEELDIRK EGGINKIRINA MARGINERANDY ALBRECHTANICE LOWENGENE TANTEDDY WOHLBOLD CAITLIN MULLARKEYNICK HEATONRONG HAIVICTOR LEYVA-GRADORAFFAEL NACHBAGAUERPAUL LEONCHRIS SEIBERTCHI-JENE CHENPETER GOFFMEGAN ERMLERSupported by NIH, PATH, GSK and BMGF